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Abstract
Background: To evaluate changes in total choline (tCho) absolute concentration ([tCho]) in the breast of healthy
fertile women in relation to menstrual cycle (MC) or use of oral contraceptives (OC).
Methods: After institutional review board approval, we prospectively evaluated 40 healthy fertile volunteers: 20
with physiological MC, aged 28 ± 3 years (mean ± standard deviation; nOC group); 20 using OC, aged 26 ± 3 years
(OC group). Hormonal assays and water-suppressed single-voxel 3-T proton magnetic resonance spectroscopy
(1H-MRS) were performed on MC days 7, 14, and 21 in the nOC group and only on MC day 14 in the OC group.
[tCho] was measured versus an external phantom. Mann-Whitney U test and Spearman coefficient were used; data
are given as median and interquartile interval.
Results: All spectra had good quality. In the nOC group, [tCho] (mM) did not change significantly during MC:
0.8 (0.3–2.4) on day 7, 0.9 (0.4–1.2) on day 14, and 0.4 (0.2–0.8) on day 21 (p = 0.963). In the OC group, [tCho] was
0.7 (0.2–1.7) mM. The between-groups difference was not significant on all days (p ≥ 0.411). All hormones except
prolactin changed during MC (p ≤ 0.024). In the OC group, [tCho] showed a borderline correlation with estradiol
(r = 0.458, p = 0.056), but no correlation with other hormones (p ≥ 0.128). In the nOC group, [tCho] negatively
correlated with prolactin (r = -0.587, p = 0.006) on day 7; positive correlation was found with estradiol on day 14
(r = 0.679, p = 0.001).
Conclusions: A tCho peak can be detected in the normal mammary gland using 3-T 1H-MRS. The [tCho] in healthy
volunteers was 0.4–0.9 mM, constant over the MC and independent of OC use.
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Key points
 Using 3-T magnetic resonance spectroscopy, a total
choline peak may be detected in normal breast tissue.
 Absolute total choline concentration does not
change with menstrual cycle when not using
contraceptives.
 Use of oral contraceptives does not impact on
absolute total choline concentration.
 No clear correlation exists between absolute total
choline concentration and sex hormones.
Background
Proton magnetic resonance spectroscopy (1H-MRS) al-
lows non-invasive metabolic imaging analyses of biologic
tissues and organs, including the human breast [1–5],
and may increase the positive predictive value of mag-
netic resonance imaging (MRI) when used for breast
cancer detection [3, 6, 7]. Systematic reviews of 1H-MRS* Correspondence: gianni.dileo77@gmail.com
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of breast lesions have shown a pooled sensitivity be-
tween 71% and 74% and a pooled specificity between
78% and 88% [8–12].
The role of 1H-MRS in breast examination is typically
based on the detection of the so-called total-choline
(tCho) peak, which is mainly the result of resonances be-
tween 3.14 and 3.34 ppm arising from the trimethylam-
monium headgroups of water-soluble choline-containing
metabolites, i.e., glycerophosphocholine, phosphocho-
line, and free choline [12]. Increased tCho concentra-
tions ([tCho]) up to 2.2 mM (range of 0.0–8.5 mM) have
been reported at 4.0 T in cancer lesions [2] and are
mostly attributed to increases in phosphocholine as a
consequence of increased metabolic turnover of
phospholipid precursors and derivatives. Using opti-
mised pre-processing, Stanwell et al. [13] have also
shown the capability at 1.5 T to distinguish phosphocho-
line resonance from the tCho large peak, although this
result was not confirmed by other authors.
The value of tCho-based MRS as an early predictor of
tumour response to neoadjuvant chemotherapy has been
proven. A 2009 1.5-T 1H-MRS study by Baek et al. [14]
assessed 35 breast cancer patients from before neoadju-
vant chemotherapy to the first follow-up assessment
after one to two cycles of doxorubicin and cyclophos-
phamide and a second assessment after another two cy-
cles. The authors reported that, at second follow-up,
patients with a pathologically complete response had a
significantly greater reduction in [tCho] relative to the
change in tumour size than those who had an incom-
plete response.
Little is still known about the tCho levels in normal
mammary gland. According to studies on excised human
tissues and cell cultures, the biochemical profile of nor-
mal gland is considered similar to that of benign lesions,
in which substantially lower tCho levels are usually de-
tected compared to cancer lesions [15].
During the menstrual cycle, breast tissues undergo
changes, including proliferation, differentiation, and re-
gression [16]. These changes were demonstrated to pro-
duce variations of background parenchymal enhancement
on contrast-enhanced MRI [17, 18]. In particular, back-
ground enhancement is lower in the follicular than in the
luteal phase [19]. Thus, it is highly recommended to
schedule contrast-enhanced breast MRI during the follicu-
lar phase (from day 5 to day 12 after the start of the men-
strual cycle) to avoid an assumed risk of false-positive
diagnoses [17]. Importantly, no changes in MRI parame-
ters have been reported in young women using oral con-
traceptives (OC) [20].
As tCho may be used as a biomarker of breast cancer,
it is important to assess whether its 1H-MRS resonance
normally changes during the menstrual cycle, as these
changes could act as a confounding factor in diagnosis.
Moreover, it is also important to evaluate the effect of
OC use on the tCho level in the normal breast.
Thus, our aims were: 1) to measure [tCho] in the nor-
mal mammary gland of young healthy women and to de-
termine whether it varies during the menstrual cycle;
and 2) to compare women not using OC with those
using OC.
Methods
Study design and population
This prospective longitudinal study was approved by our
institutional review board and written informed consent
was obtained from all participants.
A total of 40 healthy fertile volunteers without family
history of breast or ovarian cancer entered this study.
All women underwent initial clinical examination and
breast ultrasound to check for compliance with inclusion
criteria. Exclusion criteria were: previous breast surgery,
recent breast feeding, presence of breast nodules or cysts
larger than 1 cm, and contraindications to undergo MRI.
Volunteers were divided into two groups according to
whether they had a physiological menstrual cycle or they
used OC, as follows: a group called “nOC” included 20
women with physiological menstrual cycle, aged 28 ± 3 years
(mean ± standard deviation; median 27); a group called
“OC” included 20 women using OC, aged 26 ± 3 years (me-
dian 26). The mean body mass index ± standard deviation
was 21 ± 3 kg/m2 for the nOC group and 20 ± 2 kg/m2 for
the OC group; the mean age at menarche ± standard devi-
ation was 12 ± 1 year and 13 ± 1 year, respectively.
Hormonal assay
Each participant underwent a hormonal assay using a
radioimmunoassay technique based on labeled antigen–
antibody binding [21]. Estradiol, progesterone, follicle
stimulating hormone, luteinising hormone, and prolactin
were measured. Women in the nOC group underwent
hormonal assay three times, on days 7, 14, and 21 of the
menstrual cycle; women in the OC group underwent
hormonal assay only once, on day 14.
1H-MRS protocol
As for the hormonal assay, women in the nOC group
underwent 1H MRS three times, on days 7, 14, and 21 of
the menstrual cycle; women in the OC group underwent
1H MRS only once, on day 14.
All MRS studies were performed using a 3-T unit
(General Electric Healthcare, Discovery MR 750, Little
Chalfont, UK). Automated shimming was performed be-
fore each examination. Water suppressed single-voxel
MRS was acquired using a point-resolved MRS sequence
(repetition time 1,500 ms, echo time 135 ms, number of
excitations 82) and a bilateral dedicated eight-channel
breast coil with the patient in the prone position. A
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repetition time of 1,500 ms was chosen to shorten the
acquisition time and avoid participants’ movement. An
isotropic voxel of 2 × 2 × 2 cm3 was placed on the most
homogeneous part of the mammary gland, thus avoiding
partial-volume effects (Fig. 1).
All spectra were processed by a physicist with 5 years
of experience using the software provided by the manu-
facturer (SAGE, v07, General Electric Healthcare, Little
Chalfont, UK). After filtering and baseline and phase
correction, the peak amplitude of tCho (centred at about
3.2 ppm) was measured in arbitrary units (au).
The formula by Bolan [22] was used to correct the
peak amplitude of tCho (tCho'):
tCho
0 ¼ tCho
f gain f coil f T1 f T2
with correction factors:
f gain ¼ gain=gain0
f coil ¼ B1=B1;0
f T 1 ≈ 1−e
−TRT1
f T 2 ¼ e
−TET2
where gain is the receiver gain and B1 is the local ampli-
tude of the excitation radiofrequency field, both re-
trieved from DICOM metadata. T1 and T2 relaxation
times of choline were taken from the literature as being
870 ms and 400 ms, respectively. After these corrections
are made, the signal amplitude is proportional to the
number of nuclei in the volume [22].
To quantify the absolute [tCho], expressed as mM, the
same MRS protocol and the same fitting procedure were
applied once to a commercial phantom containing cho-
line at a known concentration of 2 mM. In general, the
corrected signal amplitude A' of a resonance is propor-
tional to the number of nuclei n in the sample: n =
ksysA
'. The system constant ksys accounts for the
system-specific hardware and software. The externally
referenced [tCho] was then expressed as:
tCho½  ¼ tCho
f gain f coil f T 1 f T 2
ksys
ρph
where ρph was the phantom density, assumed to be
1 kg/L.
Statistical analysis
The statistical analysis was performed using the SPSS
software package (SPSS IBM inc. v19, Chicago, IL,
USA). A p value < 0.05 was regarded as significant.
Considering the small sample size, continuous tCho
data were reported as median and interquartile interval
(25th–75th percentile) and non-parametric statistics
were adopted.
Age, body mass index, and age at menarche were
presented as mean ± standard deviation; differences
between the two groups were ascertained using the
Student t test.
For the nOC group, changes over the menstrual cycle of
[tCho] and hormones were assessed using the Friedman
test. The [tCho] measured in the OC group was compared
to [tCho] measured in the nOC group at days 7, 14, and
21 of the menstrual cycle using the Mann-Whitney U test.
In both groups, [tCho] was correlated to concentration of
hormones using the Spearman correlation coefficient.
Results
Distributions and associations
The two groups were homogeneous in terms of mean
age and body mass index (p ≥ 0.250) but women in the
nOC group had a slightly lower age at menarche than
women in the OC group (12 ± 1 years versus 13 ± 1 years,
p = 0.028).
None of the examinations were interrupted and all
acquired spectra were of good quality. An example of
1H-MRS obtained in a woman from the OC group is
shown in Fig. 2: a clear tCho peak was visible at about
Fig. 1 Placement of the volume of interest for spectrum acquisition
into the most homogeneous part of the gland
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3.2 ppm, for an absolute [tCho] of 0.1 mM. Another ex-
ample of a woman in the nOC group is shown in Fig. 3,
for an absolute [tCho] of 0.6 mM. This sample shows
that tCho can be detected and quantified in normal
breast tissue at 3 T. The spectrum obtained in the phan-
tom led to ksys of 3.4 × 10
-6 mmol/au.
In the nOC group, [tCho] did not change significantly
during the menstrual cycle. The median [tCho] in the
nOC group was 0.8 (0.3–2.4) mM on day 7, 0.9 (0.4–1.2)
mM on day 14, and 0.4 (0.2–0.8) mM on day 21, the dif-
ferences being not statistically significant (p = 0.963). Per
comparison, the [tCho] in the OC group (measured once)
was 0.7 (0.2–1.7) mM. The difference between the [tCho]
measured in the two groups was not statistically signifi-
cant for all days (p ≥ 0.411).
These data and distributions of hormones are shown
in Table 1. All hormones except prolactin showed varia-
tions during the menstrual cycle (p ≤ 0.024).
Correlation analysis
In the OC group, [tCho] showed a borderline positive
correlation only with estradiol (r = 0.458, p = 0.056); no
correlation was found with other hormones (p ≥ 0.128).
In the nOC group, [tCho] negatively correlated with pro-
lactin (r = -0.587, p = 0.006) but only on day 7, while a
positive correlation was also found with estradiol only
on day 14 (r = 0.679, p = 0.001).
Discussion
Most of the previous studies using 1.5-T magnets re-
ported no detectable tCho levels in normal breast
gland, except in the case of breast feeding or benign
lesions [6, 23, 24]. Higher magnetic field strengths in-
crease the signal-to-noise ratio and spectral resolution
of 1H-MRS, thus allowing for a more accurate and
more sensitive metabolite quantification as well as use
of smaller acquisition voxels [25]. Indeed, using a 3-T
magnet we were able to detect and quantify tCho in
normal breast gland of young volunteers.
The most important result of this study is the demon-
stration of a nearly constant absolute [tCho] during the
menstrual cycle in women not using OC. This concen-
tration ranged from 0.4 to 0.9 mM without significant
temporal variations. During the menstrual cycle, breast
gland undergoes cyclic changes culminating in apoptosis.
Mitotic activity is higher during the luteal phase because
of a synergic role of both estradiol and progesterone
with increases in apoptotic levels on day 28, when hor-
monal levels decrease. Vogel et al. [16] identified five
specific phases on the basis of morphologic changes in
the mammary stromal and epithelial components: prolif-
erative (days 3–7), follicular phase of differentiation
(days 8–14), luteal phase of differentiation (days 15–20),
secretory (days 21–27), and menstrual (days 28–2). Ac-
cording to these findings and considering that tCho is a
marker of metabolic turnover of phospholipids in cell
membranes, we might expect different [tCho] levels be-
tween the first and the second half of the menstrual
cycle. However, we did not observe any significant dif-
ference in [tCho] during the menstrual cycle, although
we acknowledge that a higher statistical power, mean-
ing a larger sample, could perhaps demonstrate some
variation.
Fig. 2 1H-MRS of the breast gland in a healthy fertile 26-year-old woman using oral contraceptives. A clear peak of choline-containing compounds
(tCho) is visible at about 3.2 ppm, giving an absolute concentration of 0.1 mM Three main resonances are visible at about 0.9 ppm and 1.2 ppm due
to lipids as well as at about 4.7 ppm due to unsuppressed water
Di Leo et al. European Radiology Experimental            (2018) 2:43 Page 4 of 6
The median [tCho] measured in nOC women (0.4–
0.9 mM) substantially overlaps with that obtained by
Bolan [22] using internal referencing on a 4-T magnet,
who reported a value of 0.66 ± 0.06 mM (mean ± stand-
ard deviation) in five healthy volunteers. The data re-
ported by Bolan [22] fall in the middle of our interval
together with a small standard deviation, but we should
consider that Bolan’s study did not consider the men-
strual phase. Thus, it is possible that they did not ob-
serve the full spectrum of possible tCho concentrations.
Anyway, the close similarity of our and Bolan’s results is
an indirect confirmation of the validity of the quantifica-
tion method that we used.
Another result of this study is the demonstration of a no
or negligible impact of OC on [tCho]. In fact, the median
[tCho] observed in the OC group falls within the range of
values obtained for the nOC group. This finding is in line
with another result of this study, that is, the lack of a clear
correlation between [tCho] and hormonal levels, apart
from some sporadic correlations. In practice, OC impacts
on the hormonal status but changes in hormonal levels do
not produce significant variations in [tCho].
This pilot study has some limitations. First, 1H-MRS
was performed only once in the OC group, under the as-
sumption that [tCho] was constant over the menstrual
cycle due to the OC mechanism of ovulation inhibition,
which is responsible for stable hormonal levels. Second,
even for volunteers who had a regular menstrual cycle,
we could not plan MRS examinations on day 1 of the
cycle. Thus, these data were missing, preventing us from
Table 1 Distributions of total choline-containing compounds (tCho), estradiol, progesterone, follicle stimulating hormone (FSH),
luteinising hormone (LH), and prolactin in the group of women not using oral contraceptive (nOC) and in the group of women
using oral contraceptive (OC)
OC group nOC group
Day 7 Day 14 Day 21 p value*
tCho (mM) 0.7 (0.2–1.7) 0.8 (0.3–2.4) 0.9 (0.4–1.2) 0.4 (0.2–0.8) 0.963
Estradiol (pg/mL) 30 (26–42) 74 (55–112) 136 (91–188) 152 (129–196) 0.024
Progesterone (ng/mL) 0.8 (0.5–1.0) 0.5 (0.4–0.8) 1.1 (0.7–2.1) 10.3 (1.6–16.3) < 0.001
LH (mIU/mL) 0.8 (0.3–1.7) 2.2 (2.1–3.1) 4.7 (3.3–10.0) 1.9 (0.8–5.1) 0.006
FSH (mIU/mL) 2.4 (0.9–4.2) 5.7 (4.9–8.1) 7.5 (5.5–11.0) 3.6 (2.3–5.2) 0.002
Prolactin (ng/mL) 16.7 (14.1–22.3) 14.8 (14.0–17.5) 16.5 (13.2–20.0) 14.8 (12.6–18.1) 0.541
Data are medians and interquartile intervals. In the nOC group, three measurements were made on days 7, 14, and 21 of the menstrual cycle
*This comparison was made among the three distributions measured in the nOC group as a variation during the menstrual cycle
Fig. 3 1H-MRS of the breast gland in a healthy fertile 24-year-old woman not using oral contraceptives. A clear peak of choline-containing compounds
(tCho) is visible at about 3.2 ppm, giving an absolute concentration of 0.6 mM. Three main resonances are visible at about 0.9 ppm and 1.2 ppm due to
lipids as well as at about 4.7 ppm due to unsuppressed water
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deeper investigation. Third, as already mentioned, the
sample size was small, likely preventing us from observ-
ing more subtle variations in [tCho] over the menstrual
cycle. A larger study might give deeper insights into this
issue. Fourth, we did not correct tCho peak for the coil
load and the spatial variation of the coil sensitivity, but
we assume that this does not represent a bias.
In conclusion, a tCho peak can be well detected by
3-T 1H MRS in the normal mammary gland. The [tCho]
in healthy volunteers is of the order of 0.4–0.9 mM,
without significant dependence on the phase of the men-
strual cycle and, importantly, on the use of OC.
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